Proteomic applications for the early detection of cancer

被引：697

作者：

Wulfkuhle, JD

Liotta, LA

Petricoin, EF ^{[1
]}

机构：

[1] NCI FDA Clin Proteom Program, Off Director, Ctr Biol Evaluat & Res, FDA, Bethesda, MD 20892 USA

[2] NCI, NCI FDA Clin Proteom Program, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

NATURE REVIEWS CANCER | 2003年 / 3卷 / 04期

关键词：

D O I：

10.1038/nrc1043

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The ability of physicians to effectively treat and cure cancer is directly dependent on their ability to detect cancers at their earliest stages. Proteomic analyses of early-stage cancers have provided new insights into the changes that occur in the early phases of tumorigenesis and represent a new resource of candidate biomarkers for early-stage disease. Studies that profile proteomic patterns in body fluids also present new opportunities for the development of novel, highly sensitive diagnostic tools for the early detection of cancer.

引用

页码：267 / 275

页数：9

共 92 条

[21]

Chen GA, 2002, CLIN CANCER RES, V8, P2298

[22] Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis - Evaluation of tissue preparation and sample limitations [J].